JPWO2021150570A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021150570A5 JPWO2021150570A5 JP2022544318A JP2022544318A JPWO2021150570A5 JP WO2021150570 A5 JPWO2021150570 A5 JP WO2021150570A5 JP 2022544318 A JP2022544318 A JP 2022544318A JP 2022544318 A JP2022544318 A JP 2022544318A JP WO2021150570 A5 JPWO2021150570 A5 JP WO2021150570A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- human subject
- composition according
- recombinant
- brain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062964351P | 2020-01-22 | 2020-01-22 | |
| US62/964,351 | 2020-01-22 | ||
| US202063086145P | 2020-10-01 | 2020-10-01 | |
| US63/086,145 | 2020-10-01 | ||
| PCT/US2021/014129 WO2021150570A1 (en) | 2020-01-22 | 2021-01-20 | Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua) |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023511382A JP2023511382A (ja) | 2023-03-17 |
| JPWO2021150570A5 true JPWO2021150570A5 (https=) | 2024-02-16 |
| JP2023511382A5 JP2023511382A5 (https=) | 2024-02-16 |
Family
ID=74592808
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022544318A Pending JP2023511382A (ja) | 2020-01-22 | 2021-01-20 | 完全ヒトグリコシル化ヒトα－Ｌ－イズロニダーゼ（ＩＤＵＡ）を用いたムコ多糖症Ｉ型の治療 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230059395A1 (https=) |
| EP (1) | EP4093428A1 (https=) |
| JP (1) | JP2023511382A (https=) |
| KR (1) | KR20220131522A (https=) |
| AU (1) | AU2021211416A1 (https=) |
| BR (1) | BR112022014563A2 (https=) |
| CA (1) | CA3167685A1 (https=) |
| IL (1) | IL294625A (https=) |
| WO (1) | WO2021150570A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA50016A (fr) | 2017-07-06 | 2020-07-08 | Univ Pennsylvania | Thérapie génique médiée par aav9 pour traiter la mucopolysaccharidose de type i |
| TWI835747B (zh) | 2017-09-22 | 2024-03-21 | 賓州大學委員會 | 用於治療黏多醣病 ii 型之基因治療 |
| CA3167741A1 (en) * | 2020-01-29 | 2021-08-05 | Regenxbio Inc. | Treatment of mucopolysaccharidosis ii with recombinant human iduronate-2-sulfatase (ids) produced by human neural or glial cells |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1916258E (pt) | 1999-08-09 | 2014-07-29 | Genzyme Corp | Aumento da expressão de uma sequência nucleotídica heteróloga de cadeia simples a partir de vectores virais recombinantes por concepção da sequência de maneira que esta forme pares de bases intracadeia |
| NZ532635A (en) | 2001-11-13 | 2007-05-31 | Univ Pennsylvania | A method of identifying unknown adeno-associated virus (AAV) sequences and a kit for the method |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| CN1856576B (zh) | 2003-09-30 | 2011-05-04 | 宾夕法尼亚州立大学托管会 | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 |
| WO2006110689A2 (en) | 2005-04-07 | 2006-10-19 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
| EP1777906A1 (en) | 2005-06-09 | 2007-04-25 | Matsushita Electric Industrial Co., Ltd. | Amplitude error compensating apparatus and orthogonality error compensating apparatus |
| WO2010138263A2 (en) | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| EP2634253B1 (en) | 2010-10-27 | 2016-05-11 | Jichi Medical University | Adeno-associated virus virions for transferring genes into neural cells |
| WO2012109570A1 (en) | 2011-02-10 | 2012-08-16 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| HRP20171334T1 (hr) | 2011-04-22 | 2017-11-17 | The Regents Of The University Of California | Virioni adeno-povezanog virusa s kapsid varijantom i postupci njihove upotrebe |
| ES2857773T5 (es) | 2011-08-24 | 2024-06-04 | Univ Leland Stanford Junior | Nuevas proteínas de la cápside de AAV para la transferencia de ácidos nucleicos |
| WO2013170078A1 (en) | 2012-05-09 | 2013-11-14 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| EP2970946A4 (en) | 2013-03-13 | 2016-09-07 | Philadelphia Children Hospital | ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF |
| US9585971B2 (en) | 2013-09-13 | 2017-03-07 | California Institute Of Technology | Recombinant AAV capsid protein |
| HUE052676T2 (hu) | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik |
| WO2015164757A1 (en) | 2014-04-25 | 2015-10-29 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| EP3411488A1 (en) * | 2016-02-03 | 2018-12-12 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type i |
| JP7042814B2 (ja) * | 2016-11-01 | 2022-03-28 | 日本光電工業株式会社 | 患者の頭部に配置されて当該患者の脳の皮質組織の脈動を測定するためのトランスデューサを含むシステム |
| EP3541946A1 (en) * | 2016-11-15 | 2019-09-25 | Regents Of The University Of Minnesota | Method for improving neurological function in mpsi and mpsii and other neurological disorders |
| CA3049915A1 (en) * | 2017-01-31 | 2018-08-09 | Stephen YOO | Treatment of mucopolysaccharidosis i with fully-human glycosylated human alpha-l-iduronidase (idua) |
| MA50016A (fr) * | 2017-07-06 | 2020-07-08 | Univ Pennsylvania | Thérapie génique médiée par aav9 pour traiter la mucopolysaccharidose de type i |
-
2021
- 2021-01-20 WO PCT/US2021/014129 patent/WO2021150570A1/en not_active Ceased
- 2021-01-20 JP JP2022544318A patent/JP2023511382A/ja active Pending
- 2021-01-20 CA CA3167685A patent/CA3167685A1/en active Pending
- 2021-01-20 AU AU2021211416A patent/AU2021211416A1/en not_active Abandoned
- 2021-01-20 EP EP21705055.8A patent/EP4093428A1/en active Pending
- 2021-01-20 US US17/792,960 patent/US20230059395A1/en active Pending
- 2021-01-20 BR BR112022014563A patent/BR112022014563A2/pt not_active Application Discontinuation
- 2021-01-20 KR KR1020227025630A patent/KR20220131522A/ko active Pending
- 2021-01-20 IL IL294625A patent/IL294625A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI832036B (zh) | 用於aav之遞送之組合物及方法 | |
| IFNB Multiple Sclerosis Study Group | Interferon beta‐1b is effective in relapsing‐remitting multiple sclerosis: I. Clinical results of a multicenter, randomized, double‐blind, placebo-controlled trial | |
| JP7832758B2 (ja) | Ｎｔ－３遺伝子治療のための方法及び材料 | |
| JP2020537637A5 (https=) | ||
| Wang et al. | Systemic administration of scAAV9-IGF1 extends survival in SOD1G93A ALS mice via inhibiting p38 MAPK and the JNK-mediated apoptosis pathway | |
| JP2020526514A5 (https=) | ||
| CN110325219B (zh) | 编码甲基-CpG结合蛋白2的重组腺相关病毒的鞘内递送 | |
| JP2024112876A5 (https=) | ||
| Wagner | Approaching a new age in Duchenne muscular dystrophy treatment | |
| WO2017106244A1 (en) | Compositions and methods for regulatable antibody expression | |
| JP2020508289A5 (https=) | ||
| Qi et al. | Long-term suppression of neurodegeneration in chronic experimental optic neuritis: antioxidant gene therapy | |
| JP2021534154A5 (https=) | ||
| JPWO2021150570A5 (https=) | ||
| JP2023159405A5 (https=) | ||
| WO2023169115A1 (zh) | 一种神经系统高亲和性的aav载体及其应用 | |
| AU2025248711A1 (en) | Gene Therapy For Addiction Disorders | |
| JP2020522524A5 (https=) | ||
| JPWO2022046988A5 (https=) | ||
| JPWO2023186830A5 (https=) | ||
| Venkataramaiah et al. | Management of myasthenia gravis | |
| EP4100021A1 (en) | Microrna-7 compositions for promoting functional recovery following spinal cord injury and methods of use thereof | |
| US20240398830A1 (en) | Compositions and uses thereof for treatment of neurological disorders | |
| JPWO2019197406A5 (https=) | ||
| WO2023158300A1 (en) | Polyomaviral gene delivery vector particle comprising a nucleic acid sequence encoding a phosphatase activity-possessing polypeptide |